AcelRx Pharmaceuticals, Inc. ACRX, (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of 1-for-20. The reverse stock split will become effective at 5:01 p.m. ET on Tuesday, October 25, 2022. AcelRx's common stock will continue to be traded on the Nasdaq Global Market under the symbol ACRX and will begin trading on a split-adjusted basis when the market opens on Wednesday, October 26, 2022. The reverse stock split is intended to enable AcelRx to regain compliance with the $1.00 minimum bid price required for continued listing on the Nasdaq Global Market. The new CUSIP number for AcelRx's common stock following the reverse stock split will be 00444T209.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.